Establishment of individualized dosage regimen based on pharmacodynamic model considering efficacy expression process of biological agents for rheumatoid arthritis

考虑类风湿关节炎生物制剂药效表达过程的药效模型个体化给药方案的建立

• 批准号: 21590181
• 负责人: YAMADA Yasuhiko
• 金额: $ 3.08万
• 依托单位: Tokyo University of Pharmacy and Life Science
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2009
• 资助国家: 日本
• 起止时间: 2009 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21590181/
• 关键词: 医薬品情報・安全性学; 投与設計; 臨床; 薬剤反応性; 薬学; 遺伝子; リウマチ; TNFα; 薬物反応生; モデリング

Based on pharmacodynamic model for pharmacotherapy of rheumatoid arthritis, it was thought that the effect of infliximab appeared comparatively early, although its variation was large. In contrast, the effects of adalimumab and etanerscept appeared slowly, whereas these were stably. Regarding the individual variation, the level of TNFα by the influence of single nucleotide polymorphisms(SNPs) in TNFα gene was different. It was considered that dosage regimen of each drug for individual patient can be established with the developed model in view of the individual quantitative factor of TNFα.

基于药物治疗类风湿关节炎的药效学模型，认为英夫利西单抗的作用出现相对较早，但其变异性较大。相比之下，阿达木单抗和依那西普的作用出现缓慢，而这些作用稳定。TNFα基因单核苷酸多态性（SNPs）对TNFα水平的影响存在个体差异。根据TNFα的个体定量因素，认为所建立的模型可用于制定个体患者的每种药物给药方案。

项目成果

Theory-based analysis of anti-inflammatory effect of infliximab on Crohn's disease and rheumatoid arthritis

• DOI: 10.1007/s00296-010-1553-8
• 发表时间: 2012-01-01
• 期刊: RHEUMATOLOGY INTERNATIONAL
• 影响因子: 4
• 作者: Kimura, Koji;Takayanagi, Risa;Yamada, Yasuhiko
• 通讯作者: Yamada, Yasuhiko